Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.

Trial Details

NCT ID
NCT07522151
Phase
PHASE3
Sponsor
Shanghai Shengdi Pharmaceutical Co., Ltd
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Adebrelimab plus S-1 and oxaliplatin
  • Adebrelimab blank preparation plus S-1 and oxaliplatin.
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients with pathologically confirmed gastric cancer or gastroesophageal junction cancer.
  • Age: ≥18 years old, \<75 years old, both male and female are eligible.
  • Before entering the study, the investigator has evaluated and determined that the subject is suitable and plans to undergo neoadjuvant therapy + ra…
  • Gastric cancer or gastroesophageal junction cancer applicable to the 8th edition of the AJCC gastric cancer staging criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →